Adalimumab + Placebo

Phase 3Completed

2 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Crohn's Disease

Conditions

Crohn's Disease

Trial Timeline

May 1, 2014 → Jan 30, 2020

NCT ID

NCT02065570

About Adalimumab + Placebo

Adalimumab + Placebo is a phase 3 stage product being developed by AbbVie for Crohn's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02065570. Target conditions include Crohn's Disease.

What happened to similar drugs?

9 of 20 similar drugs in Crohn's Disease were approved

Approved (9) Terminated (4) Active (11)

✅adalimumabAbbVieApproved

✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved

✅Infliximab + Prednisolone + AzathioprinePfizerApproved

✅Celebrex + placeboPfizerApproved

✅Cimzia + MesalamineUCBApproved

✅Certolizumab PegolUCBApproved

✅certolizumab pegol + certolizumab pegol + certolizumab pegol + certolizumab pegolUCBApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02065557	Phase 3	Completed	Oct 13, 2014	Feb 7, 2020	Ulcerative Colitis
NCT02065570	Phase 3	Completed	May 1, 2014	Jan 30, 2020	Crohn's Disease
NCT01893996	Approved	Completed	Jul 1, 2013	Jul 1, 2017	Rheumatoid Arthritis
NCT01808118	Phase 3	Completed	Apr 16, 2013	Apr 14, 2017	Axial Spondyloarthritis
NCT01670240	Phase 3	Completed	Aug 1, 2012	Jan 1, 2016	Ulcerative Colitis
NCT01646073	Phase 3	Completed	Aug 1, 2012	Dec 1, 2013	Plaque Psoriasis
NCT01468207	Phase 3	Completed	Nov 1, 2011	Jan 1, 2014	Hidradenitis Suppurativa (HS)
NCT01468233	Phase 3	Completed	Nov 1, 2011	Apr 1, 2014	Hidradenitis Suppurativa (HS)
NCT01064856	Phase 3	Completed	Feb 1, 2010	May 1, 2014	Peripheral Spondyloarthritis

Competing Products

20 competing products in Crohn's Disease

See all competitors

Product	Company	Stage	Hype Score
CT-P13 + Remicade	Celltrion	Phase 3	40
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13	Celltrion	Phase 1	29
CT-P13 SC (Infliximab)	Celltrion	Phase 3	40
CP-461	Astellas Pharma	Phase 2	35
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kg	Eisai	Phase 1/2	32
E6011 + Placebo	Eisai	Phase 2	35
E6011 + Placebo	Eisai	Phase 1	21
adalimumab + adalimumab + placebo	Eisai	Phase 2/3	38
adalimumab	Eisai	Phase 2/3	38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + Placebo	Eli Lilly	Phase 3	40
Mirikizumab	Eli Lilly	Phase 3	47
Mirikizumab + Mirikizumab + Tirzepatide + Placebo	Eli Lilly	Phase 3	47
Mirikizumab + Placebo	Eli Lilly	Phase 2	35
Mirikizumab	Eli Lilly	Phase 3	44
Matching Placebo for Upadacitinib + Upadacitinib	AbbVie	Phase 3	40
Upadacitinib + Placebo for Upadacitinib	AbbVie	Phase 3	40
Placebo + ABT-494	AbbVie	Phase 2	35
ABT-494	AbbVie	Phase 2	35
Risankizumab + Comparator	AbbVie	Pre-clinical	33
placebo for risankizumab + risankizumab IV + risankizumab SC	AbbVie	Phase 3	40